跳至主要内容
临床试验/NCT00190606
NCT00190606已完成2 期

Efficacy and Safety of Duloxetine Compared With Placebo,Pelvic Floor Muscle Training, and Combined Duloxetine/Pelvic Floor Muscle Training in Subjects With Moderate to Sever Stress Urinary Incontinence

Eli Lilly and Company3 个研究点 分布在 2 个国家目标入组 200 人开始时间: 2002年1月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
200
试验地点
3
主要终点
Effectiveness of combined duloxetine and PFMT with combined placebo and imitation PFMT in women with SUI as measured by percent change in Incontinence Episode Frequency from baseline to endpoint.

研究概览

简要总结

The study is a comparison of the efficacy and safety of duloxetine and pelvic floor muscle training with that of placebo in patients with moderate to severe stress urinary incontinence

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Between 18 and 75 years of age
  • Confirmed pure genuine stress incontinence
  • Have discrete episodes of incontinence
  • Have pelvic organ prolapse of no greater than Stage II

排除标准

  • Positive urine culture at visit 1
  • Had formal PFMT with instruction
  • Use of MAOI or other excluded medications
  • Use of any anti-incontinence device, vaginal pessaries or any medication prescribed for the treatment of urinary incontinence

结局指标

主要结局

Effectiveness of combined duloxetine and PFMT with combined placebo and imitation PFMT in women with SUI as measured by percent change in Incontinence Episode Frequency from baseline to endpoint.

Effectiveness of combined duloxetine and PFMT with combined placebo and PFMT for up to 12 weeks in women with SUI as measured by percent change in Incontinence Episode Frequency from baseline to endpoint.

次要结局

  • Incontinence Quality of Life scores from baseline to endpoint.
  • Symptoms Frequency & Bothersomeness.
  • Patient Global Impression - Impression at endpoint.
  • Percent change in weekly continence pad usage (CPAD) from baseline to endpoint.
  • Change in Patient Satisfaction Questionnaires -2 and -4 questionnaire scores from baseline to endpoint.
  • Percent change in daily CPAD from baseline to endpoint.
  • Compare safety of duloxetine with placebo based on vital signs , laboratory values and the occurrence of treatment-emergent adverse events.
  • Compare combined duloxetine and PFMT, combined duloxetine and imitation PFMT, combined placebo with PFMT and combined placebo and imitation PFMTwith respect to efficacy and to safety.
  • Compare the effect of duloxetine and placebo on patient compliance to PFMT and imitation PFMT regimes using a daly patient-generated log of completed contractions.
  • Generate long-term safety data (during open-label extension) on duloxetine in the treatment of women with SUI.

研究者

申办方类型
Industry

研究点 (3)

Loading locations...

相似试验